China
Africa
Explore chapters and articles related to this topic
Digital Monitoring
Published in Ashfaq A Marghoob, Ralph Braun, Natalia Jaimes, Atlas of Dermoscopy, 2023
Harald Kittler, Scott W. Menzies
About 75% of lentigo maligna will change within 3 months. In 25% cases of lentigo maligna melanoma, the changes develop more gradually, and thus, a longer follow-up interval is necessary to detect these melanomas. We are of the opinion that a 6- to 12-month follow-up interval will suffice for detecting most lentigo maligna melanomas.
General Surgery
Published in Tjun Tang, Elizabeth O'Riordan, Stewart Walsh, Cracking the Intercollegiate General Surgery FRCS Viva, 2020
Rebecca Fish, Aisling Hogan, Aoife Lowery, Frank McDermott, Chelliah R Selvasekar, Choon Sheong Seow, Vishal G Shelat, Paul Sutton, Yew-Wei Tan, Thomas Tsang
A melanoma is a malignant tumour of epidermal melanocytes. The most common subtypes are: Superficial spreading (60%): Raised plaque with variegated pigmentation and irregular borders.Nodular (30%): Darkly pigmented nodule which can ulcerate or bleed. Around 5% are amelanotic.Lentigo maligna melanoma (7%): Arise from lentigo malignas and seen in older patients. A lentigo maligna is a macular lesion which contains an increased number of abnormal melanocytes within the epidermis.Acral lentiginous melanoma (3%): More common in dark-skinned individuals and are typically subungal or on the palms or soles of the feet. Subungual melanomas appear as nail discolouration or a line of pigmentation on the nail.
Melanoma-associated emergencies
Published in Biju Vasudevan, Rajesh Verma, Dermatological Emergencies, 2019
Vidya Kharkar, M. R. L. Sujata
Lentigo maligna melanoma presents as a slowing growing or changing patch of discolored skin with variegated shape and color. They often show slow progressive changes from in situ lentigo maligna (LM) to invasive LMM and may be detected using the ABCDE rule.
Periocular invasive melanoma manifestation in a patient using bimatoprost: case report and literature review
Published in Orbit, 2023
Adam P. Deveau, Flávia Nagel da Silva, Thai Yen Ly, Ahsen Hussain
A 4 mm punch biopsy of the central part of the lesion was performed and submitted for histopathological examination in formalin. This exhibited melanoma in situ. The patient was planned for a staged excision and reconstruction using a modified square technique. At the following visit, an excisional biopsy with marked margins was performed, and the subsequent defect is shown in Figure 2. Histopathology demonstrated extensive lentigo maligna (melanoma in situ) and superficially invasive malignant melanoma with a Breslow thickness of 0.2 mm (Figure 3). On margin clearance, subsequent reconstruction was performed using a full thickness skin graft from the left preauricular region combined with direct closure and tissue advancement (Figure 4).
Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis
Published in Expert Opinion on Drug Safety, 2022
Jun Miyoshi, Minoru Matsuura, Tadakazu Hisamatsu
Malignancy was observed in 7 of 825 patients treated with UST in the UNIFI induction and maintenance phases. Among these, there was one case each of prostate cancer, colon cancer, renal papillary cancer, and rectal cancer, and three cases of non-melanoma skin cancer. One of 319 patients treated with placebo developed testicular cancer [15]. In the UST arm of the UNIFI-LTE study [34], three patients with UST developed non-melanoma skin cancers, two patients developed basal cell carcinoma, and one patient developed concurrent squamous cell carcinoma and basal cell carcinoma. In the placebo group, one patient developed basal cell carcinoma and one developed lentigo maligna melanoma. No other cancer was reported in this extension study.
Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma
Published in OncoImmunology, 2021
Marius Ilié, Elisabeth Lantéri, Emmanuel Chamorey, Brice Thamphya, Marame Hamila, Henri Montaudié, Alexandra Picard-Gauci, Sophie Gardrat, Thierry Passeron, Sandra Lassalle, Elodie Long-Mira, Julien Cherfils-Vicini, Eric Gilson, Véronique Hofman, Paul Hofman
Of the 125 patients included for analysis, 41 (32.8%) were female and 84 (67.2%) were male patients. Overall median age was 64.2 y (range, 23–92 y). A majority of patients had an ECOG status equal to 0 (97, 77.6%). Of the 125 cases, superficial spreading malignant melanoma accounted for 44.8%, nodular melanoma 25.6%, acral lentiginous melanoma 4.8%, invasive lentigo maligna melanoma 4%, and 20.8% of the cases were not classified. 32% of the cases harbored a BRAF mutation on exon 15.